Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade.
作者信息
Barragan Isabel
机构信息
Instituto de investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, Campus de Teatinos s/n, Málaga, 29010, Spain; Laboratorio de Biología Molecular del Cáncer (LBMC), Centro de investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga (UMA), C/ Marqués de Beccaría n°3, 29010, Málaga, Spain; Unidad de gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Campus de Teatinos s/n, 29010, Málaga, Spain; Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
出版信息
EBioMedicine. 2020 Oct;60:103005. doi: 10.1016/j.ebiom.2020.103005. Epub 2020 Sep 26.
Abstract
摘要
相似文献
1
Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade.
EBioMedicine. 2020 Oct;60:103005. doi: 10.1016/j.ebiom.2020.103005. Epub 2020 Sep 26.
2
Epigenetics meets immune checkpoints.
Semin Oncol. 2015 Jun;42(3):506-13. doi: 10.1053/j.seminoncol.2015.02.003. Epub 2015 Feb 14.
3
Translational Control of Immune Evasion in Cancer.
Trends Cancer. 2021 Jul;7(7):580-582. doi: 10.1016/j.trecan.2021.04.002. Epub 2021 May 7.
4
The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
Front Immunol. 2022 Jan 6;12:802049. doi: 10.3389/fimmu.2021.802049. eCollection 2021.
5
Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma.
Int J Mol Sci. 2021 Mar 22;22(6):3228. doi: 10.3390/ijms22063228.
6
Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
Front Immunol. 2021 Oct 21;12:781872. doi: 10.3389/fimmu.2021.781872. eCollection 2021.
7
Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Front Immunol. 2021 Mar 30;12:652160. doi: 10.3389/fimmu.2021.652160. eCollection 2021.
8
Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
Immunol Lett. 2020 May;221:72-74. doi: 10.1016/j.imlet.2020.02.007. Epub 2020 Feb 21.
9
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
Mol Cancer. 2021 Nov 10;20(1):146. doi: 10.1186/s12943-021-01442-3.
10
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.
J Immunol Res. 2020 Aug 4;2020:2640273. doi: 10.1155/2020/2640273. eCollection 2020.
引用本文的文献
1
Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity.
Cancers (Basel). 2022 Dec 28;15(1):184. doi: 10.3390/cancers15010184.
本文引用的文献
1
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
EBioMedicine. 2020 Sep;59:102962. doi: 10.1016/j.ebiom.2020.102962. Epub 2020 Aug 30.
2
The Contribution of Epigenetics to Cancer Immunotherapy.
Trends Immunol. 2020 Aug;41(8):676-691. doi: 10.1016/j.it.2020.06.002. Epub 2020 Jul 2.
3
(, ) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma.
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2020-000552.
4
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650. doi: 10.1073/pnas.1921445117. Epub 2020 Mar 11.
5
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
J Clin Med. 2020 Jan 20;9(1):286. doi: 10.3390/jcm9010286.
6
LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer.
Cancers (Basel). 2019 Aug 20;11(8):1213. doi: 10.3390/cancers11081213.
7
The contribution of active and passive mechanisms of 5mC and 5hmC removal in human T lymphocytes is differentiation- and activation-dependent.
Eur J Immunol. 2019 Apr;49(4):611-625. doi: 10.1002/eji.201847967. Epub 2019 Feb 8.
Zotero 插件